Electronic Post Market Safety

by | May 4, 2022 | Compliance, Consulting Group, FDA, Safety, Standardization, Standards

The Food and Drug Administration (FDA) recently finalized the guidance for post-market safety reports of biologics and drugs. The new FDA guidance “Providing Submissions in Electronic Format – Post-marketing Safety Report” was published in April 2022. This guidance will assist the industry when making regulatory submissions for the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER).

The following FDA provisions set the layout for this FDA Guidance document:

  • 21 CFR 314.80 and 314.98 – New Drug Applications (NDA) and Abbreviated New Drug Application (ANDA)
  • 21 CFR 600.80 – Products with approved biologics license applications (BLA)
  • 21 CFR part 4, subpart B – Combination products with approved NDA, ANDA or BLAs
  • 21 CFR 310.305 – Prescription drugs for human use with approved NDAs or ANDAs1

The new guidance lays out how Individual Case Safety Reports (ICRS) should be filed with the FDA after a safety alert has been initiated2. A Manufacturer can submit their reports electronically in two ways to the FDA. They can submit an ICRS through the electronic submission gateway or submit manually through the safety reporting portal. Both submission methods are available 24 hours a day, 7 days a week.

The guidance recommends a manufacturer should stay consistent with the submission method utilized to avoid duplicate reports and creating confusion in the agency. The FDA Adverse Event Reporting System (FAERS) electronic submission coordinators are available to assist with the submission of post-marketing safety reports2.

FDA safety reporting often involves the submission of a series of reports consisting of initial and follow-up Individual Case Safety Reports with associated attachments throughout the life cycle of the case. If your company needs assistance with submissions of post-marketing safety reports, EMMA International can assist. Contact us by phone at 248-987-4497 or by email at info@emmainternational.com.

1FDA (April 2022) Providing Submissions in Electronic Format — Post marketing Safety Reports Retrieved on May 1, 2022, from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-submissions-electronic-format-postmarketing-safety-reports

2RAPS (April 2022), FDA finalizes electronic post marketing safety reporting guidance Retrieved on May 1, 2022, from https://www.raps.org/news-and-articles/news-articles/2022/4/fda-finalizes-electronic-postmarketing-safety-report

Sarah Koehler

Sarah Koehler

Sarah is a Quality Engineer at EMMA International. She has experience in quality assurance, change management, laboratory controls, and process/equipment validation within the pharmaceutical and medical device industry. Sarah has earned a Bachelor of Science in Chemical Engineering from Western Michigan University.

More Resources

The End of the COVID-19 Public Health Emergency

The End of the COVID-19 Public Health Emergency

After over 3 years, the COVID-19 Public Health Emergency (PHE) will end on May 11, 2023, the Biden Administration announced last week.1After 3.5 years of the modified policy to allow for amore efficient path for COVID-19-related medical products to get to market, this begs the question of how it will impact the MedTech world.
Process Validation

Process Validation

All right, you have just gotten all of your paperwork together, submitted the right forms to the right people, set up your factory, hired and trained your staff; now it’s time to make the medical devices. The regulatory nonsense is over and done, right?
The Role of Management in Product Quality

The Role of Management in Product Quality

Depending on the factory, some production employees may find it surprising that management has an important role to play in a quality system.  21 CFR 820.20 mandates that “Management with executive responsibility shall establish objectives for, and commitment to, quality”.[1]  The Federal Government expects that management takes an active interest in improving the output of their company, at least in the case of medical device manufacturers.

Ready to learn more about working with us?

Pin It on Pinterest

Share This